Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Apr;26(4):498-501.
doi: 10.1038/s41591-020-0774-y. Epub 2020 Mar 23.

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Donn J Colby  1 , Michal Sarnecki  2 , Dan H Barouch  3 , Somporn Tipsuk  1 , Daniel J Stieh  4 , Eugène Kroon  1 , Alexandra Schuetz  5   6   7 , Jintana Intasan  1 , Carlo Sacdalan  1 , Suteeraporn Pinyakorn  6   7 , Pornsuk Grandin  5 , Hongshuo Song  6   7   8 , Sodsai Tovanabutra  6   7 , Zhanna Shubin  6   7 , Dohoon Kim  6   7 , Dominic Paquin-Proulx  6   7 , Michael A Eller  6   7 , Rasmi Thomas  6   7 , Mark de Souza  1   7 , Lindsay Wieczorek  7 , Victoria R Polonis  7 , Amélie Pagliuzza  9 , Nicolas Chomont  9 , Lauren Peter  3 , Joseph P Nkolola  3 , Johan Vingerhoets  10 , Carla Truyers  10 , Maria G Pau  4 , Hanneke Schuitemaker  4 , Nittaya Phanuphak  1 , Nelson Michael  6   7 , Merlin L Robb  11   12 , Frank L Tomaka  13 , Jintanat Ananworanich  1   6   7   14
Affiliations
Randomized Controlled Trial

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Donn J Colby et al. Nat Med. 2020 Apr.

Abstract

We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).

PubMed Disclaimer

Comment in

References

    1. Nakanjako, D. et al. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. AIDS 30, 1913–1922 (2016). - DOI
    1. Deeks, G. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22, 839–850 (2016). - DOI
    1. Takata, H. et al. Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection. Sci. Transl. Med. 9, eaag1809 (2017). - DOI
    1. Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013). - DOI
    1. Barouch, D. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232–243 (2018). - DOI

Publication types

MeSH terms

Associated data

LinkOut - more resources